We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Serum Biomarker Tests Accurately Assess Stomach Mucosa Condition

By LabMedica International staff writers
Posted on 10 Mar 2009
Print article
Serum biomarker tests were evaluated for their ability to differentiate between patients with healthy or diseased stomach mucosa: i.e., those with Helicobacter pylori gastritis or atrophic gastritis.

Risks for gastric cancer or peptic ulcer diseases are low in subjects with healthy stomach mucosa but are remarkably high in those with "diseased" stomach mucosa: i.e., in those with H. pylori gastritis or atrophic gastritis. Therefore, the differentiation between patients with healthy and diseased gastric mucosa is clinically important.

In a study performed by Dr. Iijima from the Division of Gastroenterology, Tohoku University Graduate School of Medicine (Sendai, Japan) and colleagues, the GastroPanel developed by Biohit Plc (Helsinki, Finland) was evaluated. In 162 outpatients the serum or plasma levels of gastrin-17 and H. pylori antibodies were measured from the same sample using an enzyme-linked immunosorbant assay (ELISA) technique. Pepsinogen I and pepsinogen II were also measured from the same sample using a conventional Japanese technique, and by the GastroPanel examination. Gastroscopy with gastric biopsies was performed to classify the patients into those with healthy stomach mucosa, H. pylori nonatrophic gastritis, or atrophic gastritis.

Pepsinogen I and pepsinogen II assays using the GastroPanel and the Japanese methods showed a highly significant correlation. The biomarker assays revealed that 5% of subjects had advanced atrophic corpus gastritis, which was also verified by endoscopic biopsies. The GastroPanel examination revealed an additional 7 patients who had advanced atrophic gastritis limited to the antrum. When compared with the endoscopic biopsy findings, the GastroPanel examination classified patients into groups with "healthy" or "diseased" stomach mucosa with 94% accuracy, 95% sensitivity and 93% specificity.

The study was published in the February 21, 2009 World Journal of Gastroenterology.

Related Links:

Tohoku University Graduate School of Medicine
Biohit Plc



Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Total 25-Hydroxyvitamin D₂ & D₃ Assay
25-OH-VD Reagent Kit
New
Silver Member
ACTH Assay
ACTH ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.